Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryosuke Kaku

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Cancer Science|June 12, 2026
Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non-Small Cell Lung CancerKoji Teramoto, Ryosuke Kaku, Tomoyuki Igarashi, et al.
Molecular and Clinical Oncology|May 19, 2017
Clinical outcome of posterior fixation surgery in patients with vertebral metastasis of lung cancerTomoyuki Igarashi, Keigo Okamoto, Koji Teramoto, et al.
BMC Cancer|December 19, 2025
Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective studyIssei Oi, Kohei Fujita, Takuma Imakita, et al.
Thoracic Cancer|June 17, 2026
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression ManagementIssei Oi, Kohei Fujita, Takuma Imakita, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Cancer Science|June 12, 2026
Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non-Small Cell Lung CancerKoji Teramoto, Ryosuke Kaku, Tomoyuki Igarashi, et al.
Molecular and Clinical Oncology|May 19, 2017
Clinical outcome of posterior fixation surgery in patients with vertebral metastasis of lung cancerTomoyuki Igarashi, Keigo Okamoto, Koji Teramoto, et al.
BMC Cancer|December 19, 2025
Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective studyIssei Oi, Kohei Fujita, Takuma Imakita, et al.
Thoracic Cancer|June 17, 2026
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression ManagementIssei Oi, Kohei Fujita, Takuma Imakita, et al.
Pageof 4